Email Print PDF Bookmark | | More

Camurus AB

Biotech Company / Delivery

Member of Medicon Valley Alliance

Description

Camurus specialises in the development of pharmaceuticals based on advanced nanoscale delivery solutions that optimize the therapeutic performance of difficult substances, including peptides and proteins. The company's FluidCrystal® delivery systems are used in developments programs with biotech and pharmaceutical companies worldwide. Camurus also develops own drug products targeting improved performance, safety, and patient compliance of well-documented drug compounds. New candidates for oral mucositis, prostate cancer, and acromegaly are currently in clinical trials.

Drug Pipeline

Episil® [Internal project]

Episil® represents a new concept for local treatment of pain associated with oral mucositis. The product is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal® film that mechanically protects the sensitised and sore epithelium of the oral cavity. Episil® is conveniently administered from a ready to use multi-dose device.

Drug development

Therapeutical Area / Indication		Pre- clinical	Phase I	Phase II	Phase III	Phase IV
Mouth and Tooth Diseases
	Mucositis

CAM2029 [Co-developed with Novartis]

CAM2029 is a new ready-to-use, long-acting octreotide product for treatment of acromegaly and carcinoid tumours (and other gastro-entero-pancreatic neuroendocrine, GEP NE, tumours). The product consists of a lipid-based liquid administered subcutaneously as a low volume injection. Once injected the lipid constituents immediately start to self-assemble into the "active" FluidCrystal® controlled release matrix. Therapeutic plasma levels of octreotide are thereby rapidly reached and maintained over one month.

Drug development

Therapeutical Area / Indication		Pre- clinical	Phase I	Phase II	Phase III	Phase IV
Gland and Hormone Related Diseases
	Acromegaly
Cancers and Other Neoplasms
	Malignant Carcinoid Syndrome

CAM2038 [Internal project]

CAM2038 represents a new treatment concept for opiate addiction based on the well-documented anti-addiction therapeutic buprenorphine. While the current buprenorphine products on the market rely on frequent administrations of sublingual buprenorphine tablets, CAM2038 is based on a once-weekly or once-monthly subcutaneous administration that can be given by health-care professional in a clinical setting. This allows for better treatment compliance and safeguards against misuse and drug diversion.

Drug development

Therapeutical Area / Indication		Pre- clinical	Phase I	Phase II	Phase III	Phase IV
Behaviors and Mental Disorders
	Opioid-Related Disorders

Prosenze® [Internal project]

CAM2032 is a new convenient ready-to-use, long-acting leuprolide formulation being developed for long-term treatment of prostate cancer, with development also initiated for endometriosis. The product consists of a lipid-based solution filled on standard pre-filled syringes and compatible with autoinjector devices. It is administered as a low volume subcutaneous injection that rapidly transforms in situ into the "active" FluidCrystal® controlled release matrix, providing consistent plasma levels over time. CAM2032 is being developed in two product forms, a one-month depot followed by a three-month product.

Drug development

Therapeutical Area / Indication		Pre- clinical	Phase I	Phase II	Phase III	Phase IV
Cancers and Other Neoplasms
	Prostatic Neoplasms

CAM2036 [Internal project]

Drug development

Therapeutical Area / Indication		Pre- clinical	Phase I	Phase II	Phase III	Phase IV
Nutritional and Metabolic Diseases
	Diabetes Mellitus, Type 2

Jobs Top

Recruitment Options

To increase your recruitment options, Medicon Valley Online collaborates with the world's largest career network, Monster Worldwide. This gives all MVA members a better distribution and pricing of job advertisements, a free trial access to approximately 100 million CV's based in over 50 countries, and free advisory and personal contact with Monster Key Account Managers in the region.

Read about how you can benefit from this partnership.